LaunchTrends: Anoro Ellipta Wave 3 is the third of a three-wave report series designed to track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment…
Physician and Payer Perspectives as Smoking and Pollution Perils Point to Sharply Increasing COPD Incidence Chronic obstructive pulmonary disease (COPD) has become a leading case of mortality and…
How Can Novel LABA/LAMA Combinations Differentiate Themselves in an Increasingly Crowded Market? Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and…
What Does This Emerging Trend Hold for Branded Agents? Asthma and chronic obstructive pulmonary disease (COPD) are chronic diseases of the airways affecting millions of Americans and representing…
LaunchTrends: Anoro Ellipta Wave 2 is the second of a three-wave report series designed to track the postlaunch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment…
Chronic obstructive pulmonary disease (COPD) is a disease encompassing chronic bronchitis and emphysema that generally affects smokers and older patients. Current treatment of COPD is dominated by…
The U.S. market for chronic obstructive pulmonary disease (COPD) therapies consists entirely of symptomatic treatments, namely bronchodilators and anti-inflammatory agents, which improve patients…
Last Updated 2 October 2014 The sizable therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. The prevalence…
The asthma market has historically been one of the most lucrative drug markets in the pharmaceutical industry owing to a large and growing patient population. However, generic and/or branded-…
This three-wave LaunchTrends report series will track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (…
Improvements in patient access to novel treatments for chronic obstructive pulmonary disease (COPD) in Brazil and Mexico are largely dependent on the expansion of drug coverage by local authorities…
Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have the potential to be first-line chronic obstructive pulmonary disorder (COPD) therapies…
Accountable care organizations (ACOs), in which providers are held accountable for the costs of treating a payer’s patent population, will become more the rule than the exception in a year, as…
Asthma is a chronic inflammatory disorder of the airways leading to recurring episodes of wheezing, breathlessness, chest tightness, and coughing, with episodes characterized by airflow obstruction…
Amid the Emergence of a Novel Class of Dual Bronchodilators, What Are the Key Areas of Opportunity for Differentiation According to Pulmonologists and Payers? Treatment of chronic obstructive…